Weekly Recap: NASDAQ:CLDX plunge and anaphylaxis warning label
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares dropped after data showed barzolvolimab boosted efficacy and angioedema resolution by weeks 12—24 in a 24-week trial, but two probable Grade 4 anaphylaxis cases prompted company notes that FDA labeling would likely warn of hypersensitivity and anaphyl…